Veradermics is trading 4.79% higher at $135.74, with no clear company-specific catalyst identified for the November 3 move. - A market listing showed no news available for the company. - Major indices are mixed, while the provided biotech sector trend is lower; the broader-market context does not clearly explain the rise. - Positive Phase 3 results announced October 19 are earlier news and do not establish the reason for the move.